AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01928485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01928485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01538914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Postoperative pain is controlled with intravenous PCA.
Study NCT01928485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02494739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt enriched with polyphenols
Description: Yogurt enriched with polyphenols extracted from grape seeds
Study NCT02494739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt not enriched with polyphenols
Description: Yogurt not enriched with polyphenols
Study NCT04060576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a thinner needle
Description: We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
Study NCT04060576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a medium-sized needle
Description: We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
Study NCT04060576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a thickest needle
Description: We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
Study NCT00099086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Study NCT00099086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
Study NCT00099086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh analog
Description: A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Study NCT00099086 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
Study NCT02622672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water-soluble ubiquinol
Description: 100 mg/d
Study NCT02622672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: glycerin.soy-lecithin, and water
Study NCT01906788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine
Study NCT03353454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to maralixibat orally twice daily for 26 weeks.
Study NCT00667082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-0052 (marizomib) + vorinostat
Description: NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle
Study NCT03521063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Drug: Budesonide inhalation suspension
Study NCT01906788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0
Study NCT01906788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
Study NCT01662336 — intervention group
Intervention type: DRUG
Intervention: Lopinavir / ritonavir
Description: Prescribed according to the product monograph and physician's discretion.
Study NCT01662336 — intervention group
Intervention type: BEHAVIORAL
Intervention: Kaletra Adherence Support Assistance Program
Description: A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
Study NCT03521063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa
Description: Drug: Poractant alfa intratracheal suspension
Study NCT03521063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant Alfa
Description: Drug: Poractant alfa intratracheal suspension
Study NCT03521063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Sodium chloride injection 0.9%
Study NCT00038649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg orally twice daily
Study NCT03277209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
Study NCT03167593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus coryniformis K8 CECT5711
Description: Lactobacillus coryniformis CECT5711
Study NCT03167593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Description: Maltodextrin
Study NCT03841890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Clarus Video System as a video stylet
Description: video-guided intubation
Study NCT03841890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Clarus Video System as a lightwand
Description: The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
Study NCT03841890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscope
Description: Macintosh laryngoscope size 3
Study NCT02030483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
Study NCT02030483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
Study NCT02030483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
Study NCT00105573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal interpersonal psychotherapy (IP)
Description: Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
Study NCT00105573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant-parent psychotherapy
Description: Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
Study NCT04068207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Tab. Minocycline 100mg po per day for 12 months
Study NCT02045459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
Study NCT00105573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informational meetings plus treatment as usual
Description: Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
Study NCT03966482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group before-after
Description: The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
Study NCT01615042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule, daily, 50mg-100mg, one cycle (21 days)
Study NCT04656730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iberogast® and Iberogast® N
Description: Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
Study NCT04656730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberogast® and Iberogast® N
Description: Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
Study NCT02788149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Exam
Description: Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
Study NCT02247401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 DAA
Description: ABT-450/r/ABT-267 tablets
Study NCT02788149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Exam
Description: Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
Study NCT02788149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as >50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr.
Study NCT02788149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as >50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr.
Study NCT04695756 — intervention group
Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: The exposure of this observational study is the COVID-19 pandemic
Study NCT02083237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural Intervention Program
Description: People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
Study NCT00571285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 600 IU Vitamin D3 capsule daily
Study NCT00571285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 600 IU Vitamin D3 capsule daily
Study NCT00571285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 - high dose
Description: 50,000 IU Vitamin D3 capsule once a week
Study NCT00571285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given once a week
Study NCT02290275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
Study NCT02290275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
Study NCT02290275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (maltodextrin)
Description: Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
Study NCT03531190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Protein + MIX)
Description: Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
Study NCT02324010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: 100mg mane for 2 days
Study NCT02324010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive drug (Placebo)
Study NCT02247401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin tablets
Study NCT03703271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: single-agent 5-day methotrexate, two weeks a cycle
Study NCT03703271 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic repeat curettage
Description: Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Study NCT01407393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucosanol
Description: 2 tablets 3x daily for 12 weeks
Study NCT01407393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3x daily for 12 weeks
Study NCT02882815 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IrisFIT PFO Occluder
Study NCT03539861 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hemodialysis
Description: Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
Study NCT02790671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: DS-8500a 25mg tablet
Study NCT02790671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200mg itraconazole
Study NCT04314596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross Training Course
Description: One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
Study NCT04314596 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cross Training Course
Description: One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
Study NCT04314596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oceanix
Description: Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
Study NCT03571256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6-, 9-, 12-, 15-, and 18 mg oral tablets
Study NCT03332147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reference group-Earlysense system
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03168139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol - Monotherapy
Description: Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks
Study NCT03571256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID.
Study NCT03571256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID.
Study NCT02290886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous administration of placebo
Study NCT02290886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 million of MSC
Study NCT02290886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 2 million of MSC
Study NCT02290886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 4 million of MSC
Study NCT00808782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep rTMS
Description: Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
Study NCT00808782 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
Study NCT01006720 — intervention group
Intervention type: DRUG
Intervention: Sugammadex
Description: Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)
Study NCT03168139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol + Pembrolizumab - Combination Therapy
Description: Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total
Study NCT00934089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost
Description: Topical ocular solution, once-daily for 14 days
Study NCT00003473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atengenal
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT00003473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astugenal
Description: Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT00049192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00049192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00049192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00002734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa